Table 3.
Conventional prognostic factors for patients.
| Variables | OS,% | P-value | Hazard ratio | 95% CI | ||
|---|---|---|---|---|---|---|
| 1 year | 2 year | Lower | Upper | |||
| GENDER | ||||||
| Male | 74 | 34 | 1 | |||
| Female | 68.2 | 36.4 | 0.325 | 0.710 | 0.360 | 1.403 |
| AGE | ||||||
| > = 62 | 66.7 | 25 | 1 | |||
| <62 | 77.8 | 44.4 | 0.168 | 1.002 | 0.991 | 1.055 |
| TUMOR SITE | ||||||
| Cervival | 50 | 50 | 1 | |||
| Upper esophagus | 79.2 | 33.3 | 0.884 | 0.851 | 0.098 | 7.356 |
| Middle esophagus | 71.4 | 34.3 | 0.626 | 1.284 | 0.469 | 3.513 |
| Lower esophagus | 63.6 | 36.4 | 0.499 | 1.394 | 0.531 | 3.658 |
| PATHOLOGY LESION LENGTH | ||||||
| < = 5 (40) | 77.5 | 35 | 1 | |||
| >5 (32) | 65.6 | 34.4 | 0.005 | 1.149 | 1.042 | 1.268 |
| T STAGE | ||||||
| T2 | 0.85 | 0.38 | 1 | |||
| T3 | 0.75 | 0.3 | 0.9042 | 1.0763 | 0.4629 | 2.5024 |
| T4 | 0.66 | 0.36 | 0.2153 | 1.6345 | 0.7702 | 3.4688 |
| N STAGE | ||||||
| N0 | 70 | 40 | 1 | |||
| N1 | 73.6 | 34.0 | 0.835 | 1.135 | 0.345 | 3.728 |
| N2 | 77.8 | 44.4 | 0.741 | 1.172 | 0.458 | 2.996 |
| TNM stage I–II | 78.1 | 34.4 | 1 | |||
| III | 67.5 | 35 | 0.120 | 1.274 | 0.939 | 1.727 |
| GTV | ||||||
| < = 40.35 | 83.3 | 36.1 | 1 | |||
| >40.35 | 61.1 | 33.3 | 0.015 | 0.476 | 0.261 | 0.868 |
| TE | ||||||
| CR | 86.1 | 38.9 | 1 | |||
| PR | 58.3 | 30.6 | 0.042 | 1.851 | 1.024 | 3.346 |
| RADIATION DOSE | ||||||
| > = 60 | 81.5 | 40.7 | 1 | |||
| <60 | 44.4 | 16.7 | 0.050 | 0.916 | 0.807 | 1.015 |
| RADIATION TYPE | ||||||
| IMRT | 69.0 | 32.8 | 1 | |||
| 3DCRT | 85.7 | 42.9 | 0.906 | 1.043 | 0.516 | 2.108 |
3DRT, 3 dimensional conformal radiation therapy; IMRT, intensity modulated radiation therapy; GTV, Gross Tumor Volume; TE, therapeutic effect. The bold values show that the P ≤ 0.05.